Live
CellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvationCellReplaying germinal center evolution on a quantified affinity landscapeCellXenophagocytosis blockade enhances interspecies chimerismFierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buyEndpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetesEndpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearEndpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and moreFierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEsAmgenAmgen: A Biotech Giant's Path to Recovery and Growth - AOL.comAmgenAmgen: A Biotech Giant's Path to Recovery and Growth - The Motley FoolNovo NordiskNovo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026 - PR Newswire
Endpoints News 14. Apr. 2026

Parker Institute doubles down on cancer vaccines as part of ongoing reboot

Parker Institute doubles down on cancer vaccines as part of ongoing reboot

Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.